An FDA advisory board recommended withdrawing government approval for the breast cancer drug, Avastin. Pros and cons of the decision and its implications for FDA’s accelerated approval process to treat serious and life threatening diseases.

Guests

  • Gardiner Harris science reporter for "The New York Times" and author of the mystery novel 'Hazard.'
  • Dr. Peter Bach attending physician and director of the Center for Health Policy and Outcomes at Memorial Sloan-Kettering Cancer Center, and a former adviser to Medicare.
  • Dr. Carolyn Hendricks a medical oncologist affiliated with Suburban Hospital in Bethesda.
  • William Hubbard former associate commissioner for the Food and Drug Administration; spokesperson for the Alliance for a Stronger FDA

Topics + Tags

Comments

comments powered by Disqus
Most Recent Shows

Friday News Roundup – International

Friday, Aug 28 2015China's market turmoil reverberates worldwide. More than 100 people die this week in Europe's ongoing migrant crisis. And the new U.S. envoy for Syria pushes for a political solution to the civil war. A panel of journalists joins Diane for analysis of the week's top international news stories.

Friday News Roundup – Domestic

Friday, Aug 28 2015The shooting of two journalists renews calls for stricter gun controls. President Obama visits New Orleans to mark the tenth anniversary of Hurricane Katrina. And the U.S. stock market takes investors on a wild ride. A panel of journalists joins Diane for analysis of the week's top national news stories.

New Tactics In The Anti-Abortion Movement

Thursday, Aug 27 2015Abortion opponents seek details on women who get abortions and the doctors who perform them. Several states have moved to cut Planned Parenthood funding even for clinics without abortion services. Join us to discuss new tactics in the anti-abortion movement.